

Pediatric Cancer in Idaho, 1996-2006

Although relatively rare in comparison with cancer in older adults, cancer is the second leading cause of death in persons aged 1-14 years. The epidemiology of cancer among children differs markedly from that of adults, both in the patterns of anatomic sites involved and the predominant histologic types. Most notably, the tumors diagnosed in children frequently involve the hematopoietic and central nervous systems or are of mesenchymal origin. In contrast, malignancies of epithelial tissues, which are predominant in adults, are uncommon in children. Similar to adult cancers, the etiology of many childhood cancers remains unclear.

The Cancer Data Registry of Idaho receives several requests per year from physicians and others for data on pediatric cancer incidence for the State of Idaho. This report describes the incidence of pediatric cancers in Idaho, with comparisons to data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program and United States Cancer Statistics (USCS).¹⁻² SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 26 percent of the US population and is considered the standard for quality among cancer registries around the world. USCS includes data from SEER and the Centers for Disease Control and Prevention's National Program of Cancer Registries for states with high quality data. For the latest USCS report (2004 incidence data), all states but Maryland are included, representing about 98 percent of the U.S. population. USCS data are used in this report for pediatric cancer incidence rankings by state.

METHODS

The data analyzed for this report include cancers diagnosed between 1996 and 2006 among Idaho residents less than 20 years of age. Cases were grouped according to the International Classification of Childhood Cancer (ICCC) based on site and morphology coded according to ICD-O-3.³

A total of 813 cases of malignant cancer were diagnosed among Idaho resident children under the age of 20 between 1996 and 2006. It was not possible to assign a group code of the ICCC system to 2 cases. Health District was assigned from county of residence at time of diagnosis. All rates presented were calculated per million population, and are averages for the period 1996 through 2006 (rates per million, rather than per 100,000, are commonly used for pediatric cancers). Age-adjustment was performed using the direct method to the 2000 U.S. standard population. Cancer incidence, mortality and survival statistics were calculated using SEER*Stat.⁴ State rankings were obtained via CDC Wonder.²

RESULTS

A total of 811 cases that met the study criteria were diagnosed among Idaho residents aged less than 20 years between 1996 and 2006, yielding an overall age-adjusted rate of 175.8 cases per million population. In comparison, the SEER rate

for Whites was 173.8 cases per million population. The distribution of pediatric cancers by ICCC grouping was very similar for Idaho and SEER Regions. Idaho's pediatric rate of astrocytomas was about 30% higher than the rate for SEER Whites ($p < .05$). For no other ICCC grouping was there a statistically significant difference between the pediatric cancer incidence rates in Idaho and SEER Regions.

For all races combined, Idaho ranked 3rd highest among states (behind Vermont and Maine) in pediatric (ages 0-19) cancer incidence 1999-2004.² This result is partially related to differences in the distribution of race by state. Pediatric cancer incidence is higher among Whites, and Idaho has a higher proportion of White residents than many states. Among Whites, Idaho ranked 9th in pediatric cancer incidence. For ICCC major classification category III (CNS and miscellaneous intracranial and intraspinal neoplasms), Idaho had the highest incidence rate by state, 1999-2004, for all races combined and among Whites.

About 80% of children aged less than 20 years diagnosed with malignant cancer survived at least 5 years after their diagnosis, both in Idaho and SEER Regions. The 5-year relative survival rate was higher in Idaho than in SEER Regions for ICCC major classification category IX (soft tissue and other extraosseous sarcomas). For no other ICCC major classification category, nor overall, was there a statistically significant difference in 5-year relative survival between Idaho and SEER cases.

Pediatric cancer incidence increased at a rate of about 0.9% per year in Idaho from 1970 to 2006. This parallels the long term increase observed in SEER Regions from 1973 to 2006 of about 0.7% per year.

Health District I had a statistically significantly lower ($p < .05$) rate of ICCC major classification category III (CNS and miscellaneous intracranial and intraspinal neoplasms) than the State of Idaho. Health District II had a statistically significantly lower ($p < .05$) rate of pediatric cancer (all sites combined) than the State of Idaho. Health District 6 had a statistically significantly lower ($p < .05$) rate of ICCC major classification category XI (other malignant epithelial neoplasms and melanomas) than the State of Idaho. For no other ICCC major classification category was there a statistically significant difference between any health district and the State of Idaho.

From 1996 to 2006, 134 of Idaho's children aged 0-19 died from some form of cancer.⁵ The leading types of cancer mortality were leukemia and brain and other central nervous system. While pediatric cancer incidence rates have increased over time, mortality rates have decreased. From 1975-2006, pediatric cancer mortality rates have decreased about 2% per year, in Idaho and the U.S. The annual rates plotted for Idaho demonstrate large year-to-year variability that is expected due to the relatively small numbers of deaths per year. Idaho ranked 36th highest among states in pediatric (ages 0-19) cancer mortality 1996-2006.

CONCLUSIONS

These data demonstrate strong similarity in pediatric cancer incidence and survival patterns between Idaho and SEER Regions. Compared with cancer in adults, there is less geographic variability in pediatric cancer incidence. Nonetheless, Idaho ranks among the highest states in terms of pediatric cancer incidence.

Largely because of improvements in therapy for pediatric cancers, there has been a decrease in mortality rates over time. Data collected by CDRI for 2007 show that approximately 37% of pediatric patients participated in clinical trials at Idaho institutions. In addition, many pediatric cases are treated out-of-state, and may be enrolled in clinical trials through out-of-state treatment facilities. While this clinical trial participation rate is much higher than that for adults (<2%), there remains much room for improvement.

Based upon the results in this report, the Cancer Data Registry of Idaho will continue to monitor pediatric central nervous system cancer incidence statewide.

Pediatric Cancer Incidence in Idaho and SEER Regions (Ages 0-19)

Site/Type of Cancer	Idaho 1996-2006			SEER 1996-2006		
	Rate	Cases	Pop	Rate	Cases	Pop
All Sites Combined	175.8	811	4,575,570	173.8	15,920	91,431,906
I Leukemias, myeloproliferative & myelodysplastic diseases	44.9	206	4,575,570	47.6	4,405	91,431,906
I(a) Lymphoid leukemias	32.1	147	4,575,570	37.4	3,462	91,431,906
I(b) Acute myeloid leukemias	8.2	38	4,575,570	8.2	753	91,431,906
I(c) Chronic myeloproliferative diseases	2.2	10	4,575,570	0.9	77	91,431,906
I(d) Myelodysplastic syndrome and other myeloproliferative	0.9	4	4,575,570	0.3	27	91,431,906
I(e) Unspecified and other specified leukemias	1.5	7	4,575,570	0.9	86	91,431,906
II Lymphomas and reticuloendothelial neoplasms	24.8	115	4,575,570	24.8	2,238	91,431,906
II(a) Hodgkin lymphomas	13.1	61	4,575,570	13.0	1,162	91,431,906
II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)	7.6	35	4,575,570	8.3	749	91,431,906
II(c) Burkitt lymphoma	2.2	10	4,575,570	2.5	229	91,431,906
II(d) Miscellaneous lymphoreticular neoplasms	1.5	7	4,575,570	0.7	68	91,431,906
II(e) Unspecified lymphomas	0.4	2	4,575,570	0.3	30	91,431,906
III CNS and misc intracranial and intraspinal neoplasms	36.3	166	4,575,570	29.7	2,734	91,431,906
III(a) Ependymomas and choroid plexus tumor	2.0	9	4,575,570	2.6	238	91,431,906
III(b) Astrocytomas	19.3	88	4,575,570	14.6	1,337	91,431,906
III(c) Intracranial and intraspinal embryonal tumors	7.9	36	4,575,570	6.9	641	91,431,906
III(d) Other gliomas	6.3	29	4,575,570	5.0	456	91,431,906
III(e) Other specified intracranial/intraspinal neoplasms	0.6	3	4,575,570	0.4	35	91,431,906
III(f) Unspecified intracranial and intraspinal neoplasms	0.2	1	4,575,570	0.3	27	91,431,906
IV Neuroblastoma and other peripheral nervous cell tumors	6.1	28	4,575,570	8.1	770	91,431,906
IV(a) Neuroblastoma and ganglioneuroblastoma	5.8	27	4,575,570	7.8	740	91,431,906
IV(b) Other peripheral nervous cell tumors	0.2	1	4,575,570	0.3	30	91,431,906
V Retinoblastoma	3.3	15	4,575,570	3.4	326	91,431,906
VI Renal tumors	6.1	28	4,575,570	6.2	579	91,431,906
VI(a) Nephroblastoma and other nonepithelial renal tumors	5.9	27	4,575,570	5.7	538	91,431,906
VI(b) Renal carcinomas	0.2	1	4,575,570	0.5	41	91,431,906
VI(c) Unspecified malignant renal tumors	0.0	0	4,575,570	0.0	0	91,431,906
VII Hepatic tumors	1.5	7	4,575,570	2.2	209	91,431,906
VII(a) Hepatoblastoma	0.9	4	4,575,570	1.6	156	91,431,906
VII(b) Hepatic carcinomas	0.7	3	4,575,570	0.6	51	91,431,906
VII(c) Unspecified malignant hepatic tumors	0.0	0	4,575,570	0.0	2	91,431,906
VIII Malignant bone tumors	11.0	51	4,575,570	8.8	793	91,431,906
VIII(a) Osteosarcomas	7.1	33	4,575,570	4.7	423	91,431,906
VIII(b) Chondrosarcomas	0.2	1	4,575,570	0.4	33	91,431,906
VIII(c) Ewing tumor and related sarcomas of bone	2.8	13	4,575,570	3.2	286	91,431,906
VIII(d) Other specified malignant bone tumors	0.2	1	4,575,570	0.5	43	91,431,906
VIII(e) Unspecified malignant bone tumors	0.6	3	4,575,570	0.1	8	91,431,906
IX Soft tissue and other extraosseous sarcomas	11.7	54	4,575,570	12.2	1,111	91,431,906
IX(a) Rhabdomyosarcomas	5.2	24	4,575,570	4.7	430	91,431,906
IX(b) Fibrosarcomas, peripheral nerve & other fibrous	0.9	4	4,575,570	1.4	130	91,431,906
IX(c) Kaposi sarcoma	0.0	0	4,575,570	0.0	2	91,431,906
IX(d) Other specified soft tissue sarcomas	3.2	15	4,575,570	4.9	447	91,431,906
IX(e) Unspecified soft tissue sarcomas	2.4	11	4,575,570	1.1	102	91,431,906
X Germ cell & trophoblastic tumors & neoplasms of gonads	11.0	52	4,575,570	12.7	1,151	91,431,906
X(a) Intracranial & intraspinal germ cell tumors	0.6	3	4,575,570	1.9	170	91,431,906
X(b) Extracranial & extragonadal germ cell tumors	1.3	6	4,575,570	1.6	148	91,431,906
X(c) Malignant gonadal germ cell tumors	8.3	39	4,575,570	8.7	781	91,431,906
X(d) Gonadal carcinomas	0.8	4	4,575,570	0.4	37	91,431,906
X(e) Other and unspecified malignant gonadal tumors	0.0	0	4,575,570	0.2	15	91,431,906


Pediatric Cancer Incidence in Idaho and SEER Regions (Ages 0-19) - continued

Site/Type of Cancer	Idaho 1996-2006			SEER 1996-2006		
	Rate	Cases	Pop	Rate	Cases	Pop
XI Other malignant epithelial neoplasms and melanomas	18.3	86	4,575,570	17.3	1,552	91,431,906
XI(a) Adrenocortical carcinomas	0.0	0	4,575,570	0.3	31	91,431,906
XI(b) Thyroid carcinomas	6.8	32	4,575,570	6.3	562	91,431,906
XI(c) Nasopharyngeal carcinomas	0.2	1	4,575,570	0.3	25	91,431,906
XI(d) Malignant melanomas	7.4	35	4,575,570	6.5	584	91,431,906
XI(e) Skin carcinomas	0.0	0	4,575,570	0.1	8	91,431,906
XI(f) Other and unspecified carcinomas	3.9	18	4,575,570	3.8	342	91,431,906
XII Other and unspecified malignant neoplasms	0.7	3	4,575,570	0.6	52	91,431,906
XII(a) Other specified malignant tumors	0.4	2	4,575,570	0.3	30	91,431,906
XII(b) Other unspecified malignant tumors	0.2	1	4,575,570	0.2	22	91,431,906
Not classified by ICCC or in situ	0.4	2	4,575,570	0.6	58	91,431,906

Rates are per 1,000,000 and age-adjusted to the 2000 U.S. standard.

SEER data are for White race. Cases and rates are for malignant behavior only.

Statistical Note: Rates based upon 10 or fewer cases (numerator) should be interpreted with caution.




Five-Year Relative Cancer Survival by Major ICCC Classification Category

Site/Type of Cancer	Idaho 1996-2006			SEER 1996-2006		
	Cases	% Survival	95% CI	Cases	% Survival	95% CI
All Sites Combined	783	79.7%	76.6% - 82.8%	15,467	80.5%	79.7% - 81.3%
I Leukemias, myeloproliferative & myelodysplastic diseases	201	81.4%	75.7% - 87.1%	4,298	78.0%	76.6% - 79.4%
II Lymphomas and reticuloendothelial neoplasms	110	88.0%	81.3% - 94.7%	2,199	89.6%	88.2% - 91.0%
III CNS and misc intracranial and intraspinal neoplasms	159	72.3%	64.5% - 80.1%	2,652	74.4%	72.6% - 76.2%
IV Neuroblastoma and other peripheral nervous cell tumors	28	68.4%	48.6% - 88.2%	759	72.5%	68.8% - 76.2%
V Retinoblastoma	13	100.0%	100.0% - 100.0%	318	98.7%	97.1% - 100.0%
VI Renal tumors	28	87.3%	73.6% - 100.0%	569	88.8%	85.9% - 91.7%
VII Hepatic tumors	7	n/a	n/a - n/a	202	57.9%	49.9% - 65.9%
VIII Malignant bone tumors	45	53.9%	35.7% - 72.1%	757	64.8%	60.7% - 68.9%
IX Soft tissue and other extraosseous sarcomas	53	85.6%	75.4% - 95.8%	1,060	71.8%	68.7% - 74.9%
X Germ cell & trophoblastic tumors & neoplasms of gonads	52	87.7%	78.1% - 97.3%	1,124	91.5%	89.7% - 93.3%
XI Other malignant epithelial neoplasms and melanomas	84	88.1%	79.3% - 96.9%	1,479	90.7%	88.9% - 92.5%
XII Other and unspecified malignant neoplasms	3	66.7%	13.4% - 100.0%	50	68.8%	54.9% - 82.7%

Pediatric Cancer Incidence in Idaho and SEER Regions (Ages 0-19)

Year of Diagnosis	Idaho 1996-2006			SEER 1996-2006		
	Rate	Cases	Pop	Rate	Cases	Pop
Total	175.8	811	4,575,570	173.8	15,920	91,431,906
1996	173.6	69	395,663	166.8	1,366	8,156,211
1997	126.7	51	400,866	165.1	1,358	8,216,504
1998	178.2	73	406,767	177.0	1,466	8,273,535
1999	164.5	69	411,481	167.3	1,390	8,317,117
2000	146.3	61	415,037	176.8	1,472	8,337,592
2001	211.2	88	415,014	179.6	1,502	8,362,298
2002	200.5	84	416,507	186.3	1,556	8,357,620
2003	211.2	89	418,824	165.5	1,383	8,349,968
2004	180.1	77	423,264	177.8	1,493	8,357,733
2005	156.3	68	431,362	185.1	1,558	8,351,448
2006	183.3	82	440,785	163.3	1,376	8,351,880

Rates are per 1,000,000 and age-adjusted to the 2000 U.S. standard.



Pediatric Cancer Incidence in Idaho (Ages 0-19) by Health District, Major Classification Categories

Site/Type of Cancer	Health District 1			Health District 2			Health District 3		
	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases
All Sites Combined	167.0	134.9 - 204.4	94	117.5	81.8 - 163.8	36	190.4	159.9 - 224.9	138
I Leukemias, myeloproliferative & myelodysplastic diseases	47.1	30.8 - 69.1	26	16.6	5.3 - 39.6	5	55.9	40.1 - 75.8	41
II Lymphomas and reticuloendothelial neoplasms	21.0	10.9 - 36.8	12	27.0	12.2 - 52.8	9	28.0	17.1 - 43.3	20
III CNS and misc intracranial and intraspinal neoplasms	17.9	8.6 - 33.0	10	21.8	7.9 - 47.6	6	42.6	28.9 - 60.4	31
IV Neuroblastoma and other peripheral nervous cell tumors	7.6	2.1 - 19.2	4	11.7	2.4 - 33.6	3	3.8	0.8 - 11.2	3
V Retinoblastoma	1.9	0.0 - 10.2	1	0.0	0.0 - 13.3	0	2.6	0.3 - 9.4	2
VI Renal tumors	5.5	1.1 - 16.1	3	0.0	0.0 - 13.3	0	11.7	5.3 - 22.3	9
VII Hepatic tumors	0.0	0.0 - 6.6	0	0.0	0.0 - 13.3	0	0.0	0.0 - 5.0	0
VIII Malignant bone tumors	12.0	4.8 - 24.9	7	13.2	3.6 - 34.6	4	4.4	0.9 - 12.6	3
IX Soft tissue and other extraosseous sarcomas	10.5	3.9 - 23.0	6	3.9	0.1 - 21.0	1	7.0	2.3 - 16.3	5
X Germ cell & trophoblastic tumors & neoplasms of gonads	14.5	6.3 - 28.6	8	11.8	3.1 - 31.8	4	10.0	4.0 - 20.5	7
XI Other malignant epithelial neoplasms and melanomas	27.3	15.6 - 44.4	16	11.4	3.0 - 30.9	4	24.5	14.2 - 39.1	17
XII Other and unspecified malignant neoplasms	1.6	0.0 - 9.6	1	0.0	0.0 - 13.3	0	0.0	0.0 - 5.0	0

Site/Type of Cancer	Health District 4			Health District 5			Health District 6			Health District 7		
	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases	Rate	95% CI	Cases
All Sites Combined	193.4	168.8 - 220.4	224	175.1	142.6 - 212.8	101	159.2	128.9 - 194.4	96	181.2	150.1 - 216.8	121
I Leukemias...	47.7	36.0 - 61.9	56	40.3	25.6 - 60.5	23	35.3	21.9 - 54.0	21	52.3	36.2 - 73.2	34
II Lymphomas...	21.0	13.4 - 31.2	24	36.4	22.5 - 55.6	21	21.3	11.3 - 36.4	13	21.4	11.9 - 35.6	15
III CNS and...	40.2	29.5 - 53.4	47	29.6	17.3 - 47.4	17	41.4	26.8 - 61.1	25	46.3	31.1 - 66.2	30
IV Neuroblastoma...	5.7	2.3 - 11.9	7	1.8	0.0 - 9.7	1	10.0	3.7 - 21.7	6	6.3	1.7 - 16.0	4
V Retinoblastoma	4.8	1.8 - 10.6	6	3.5	0.4 - 12.6	2	3.4	0.4 - 12.3	2	3.1	0.4 - 11.2	2
VI Renal tumors	8.3	4.0 - 15.3	10	1.8	0.0 - 9.7	1	5.1	1.1 - 14.8	3	3.3	0.4 - 11.7	2
VII Hepatic tumors	3.4	0.9 - 8.6	4	3.5	0.4 - 12.5	2	0.0	0.0 - 6.1	0	1.7	0.0 - 9.1	1
VIII Malignant bone tumors	11.6	6.2 - 19.8	13	18.7	9.3 - 33.5	11	11.6	4.7 - 23.9	7	8.9	3.2 - 19.6	6
IX Soft tissue...	14.7	8.6 - 23.6	17	10.4	3.8 - 22.6	6	15.0	6.9 - 28.5	9	14.8	7.1 - 27.5	10
X Germ cell...	13.5	7.5 - 22.2	15	8.6	2.8 - 20.1	5	14.5	6.6 - 27.6	9	5.3	1.4 - 14.1	4
XI Other malig epithelial...	22.5	14.6 - 33.2	25	18.8	9.4 - 33.7	11	1.6	0.0 - 9.1	1	16.0	8.2 - 28.4	12
XII Other/unspecified...	0.0	0.0 - 3.1	0	1.8	0.0 - 10.0	1	0.0	0.0 - 6.1	0	1.6	0.0 - 8.7	1

Rates are per 1,000,000 and age-adjusted to the 2000 U.S. standard.


Confidence intervals (CIs) are 95% for rates.

Statistical Note: Rates based upon 10 or fewer cases (numerator) should be interpreted with caution.

Pediatric Cancer Mortality in Idaho and the U.S. (Ages 0-19)

Year of Death	Idaho 1996-2006			U.S. 1996-2006		
	Rate	Deaths	Pop	Rate	Deaths	Pop
Total	29.2	134	4,575,570	30.7	27,166	884,124,353
1996	35.6	14	395,663	32.2	2,494	77,624,071
1997	27.4	11	400,866	32.2	2,522	78,485,091
1998	32.1	13	406,767	30.7	2,435	79,320,164
1999	41.5	17	411,481	31.5	2,517	80,039,970
2000	21.4	9	415,037	31.3	2,523	80,545,685
2001	16.7	7	415,014	30.8	2,487	80,782,196
2002	21.5	9	416,507	31.2	2,530	80,982,963
2003	47.5	20	418,824	30.4	2,466	81,187,686
2004	37.0	16	423,264	30.4	2,481	81,479,136
2005	16.1	7	431,362	29.6	2,420	81,690,257
2006	25.3	11	440,785	27.8	2,291	81,987,134

Rates are per 1,000,000 and age-adjusted to the 2000 U.S. standard.



Appendix A

Site/histology recode based on International Classification of Childhood Cancer, Third edition (ICCC-3) based on ICD-O-3¹

Site Group	ICD-O-3 Histology (Type)	ICD-O-2/3 Site	Recode
I Leukemias, myeloproliferative diseases, and myelodysplastic diseases			
(a) Lymphoid leukemias	9820, 9823, 9826, 9827, 9831-9837, 9940, 9948	C000-C809	011
(b) Acute myeloid leukemias	9840, 9861, 9866, 9867, 9870-9874, 9891, 9895-9897, 9910, 9920, 9931	C000-C809	012
(c) Chronic myeloproliferative diseases	9863, 9875, 9876, 9950, 9960-9964	C000-C809	013
(d) Myelodysplastic syndrome and other myeloproliferative diseases	9945, 9946, 9975, 9980, 9982-9987, 9989	C000-C809	014
(e) Unspecified and other specified leukemias	9800, 9801, 9805, 9860, 9930	C000-C809	015
II Lymphomas and reticuloendothelial neoplasms			
(a) Hodgkin lymphomas	9650-9655, 9659, 9661-9665, 9667	C000-C809	021
(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)	9591, 9670, 9671, 9673, 9675, 9678-9680, 9684, 9689-9691, 9695, 9698-9702, 9705, 9708, 9709, 9714, 9716-9719, 9727-9729, 9731-9734, 9760-9762, 9764-9769, 9970	C000-C809	022
(c) Burkitt lymphoma	9687	C000-C809	023
(d) Miscellaneous lymphoreticular neoplasms	9740-9742, 9750, 9754-9758	C000-C809	024
(e) Unspecified lymphomas	9590, 9596	C000-C809	025
III CNS and miscellaneous intracranial and intraspinal neoplasms			
(a) Ependymomas and choroid plexus tumor	9383, 9390-9394	C000-C809	031
(b) Astrocytomas	9380	C723	032
	9384, 9400-9411, 9420, 9421-9424, 9440-9442	C000-C809	032
(c) Intracranial and intraspinal embryonal tumors	9470-9474, 9480, 9508	C000-C809	033
	9501-9504	C700-C729	033
(d) Other gliomas	9380	C700-C722, C724-C729, C751, C753	034
	9381, 9382, 9430, 9444, 9450, 9451, 9460	C000-C809	034

(e) Other specified intracranial and intraspinal neoplasms	8270-8281, 8300, 9350-9352, 9360-9362, 9412, 9413, 9492, 9493, 9505-9507, 9530-9539, 9582	C000-C809	035
(f) Unspecified intracranial and intraspinal neoplasms	8000-8005	C700-C729, C751-C753	036
IV Neuroblastoma and other peripheral nervous cell tumors			
(a) Neuroblastoma and ganglioneuroblastoma	9490, 9500	C000-C809	041
(b) Other peripheral nervous cell tumors	8680-8683, 8690-8693, 8700, 9520-9523	C000-C809	042
	9501-9504	C000-C699, C739-C768, C809	042
V Retinoblastoma	9510-9514	C000-C809	050
VI Renal tumors			
(a) Nephroblastoma and other nonepithelial renal tumors	8959, 8960, 8964-8967	C000-C809	061
	8963, 9364	C649	061
(b) Renal carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8155, 8190-8201, 8210, 8211, 8221-8231, 8240, 8241, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8576	C649	062
	8311, 8312, 8316-8319, 8361	C000-C809	062
(c) Unspecified malignant renal tumors	8000-8005	C649	063
VII Hepatic tumors			
(a) Hepatoblastoma	8970	C000-C809	071
(b) Hepatic carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8140, 8141, 8143, 8155, 8190-8201, 8210, 8211, 8230, 8231, 8240, 8241, 8244-8246, 8260-8264, 8310, 8320, 8323, 8401, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8576	C220, C221	072
	8160-8180	C000-C809	072
(c) Unspecified malignant hepatic tumors	8000-8005	C220, C221	073
VIII Malignant bone tumors			
(a) Osteosarcomas	9180-9187, 9191-9195, 9200	C400-C419, C760-C768, C809	081
(b) Chondrosarcomas	9210, 9220, 9240	C400-C419, C760-C768, C809	082
	9221, 9230, 9241-9243	C000-C809	082
(c) Ewing tumor and related sarcomas of bone	9260	C400-C419, C760-C768, C809	083
	9363-9365	C400-C419	083

(d) Other specified malignant bone tumors	8810, 8811, 8823, 8830	C400-C419	084
	8812, 9250, 9261, 9262, 9270-9275, 9280-9282, 9290, 9300-9302, 9310-9312, 9320-9322, 9330, 9340-9342, 9370-9372	C000-C809	084
(e) Unspecified malignant bone tumors	8000-8005, 8800, 8801, 8803-8805	C400-C419	085
IX Soft tissue and other extraosseous sarcomas			
(a) Rhabdomyosarcomas	8900-8905, 8910, 8912, 8920, 8991	C000-C809	091
(b) Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms	8810, 8811, 8813-8815, 8821, 8823, 8834-8835	C000-C399, C440-C768, C809	092
	8820, 8822, 8824-8827, 9150, 9160, 9491, 9540-9571, 9580	C000-C809	092
(c) Kaposi sarcoma	9140	C000-C809	093
(d) Other specified soft tissue sarcomas	8587, 8710-8713, 8806, 8831-8833, 8836, 8840-8842, 8850-8858, 8860-8862, 8870, 8880, 8881, 8890-8898, 8921, 8982, 8990, 9040-9044, 9120-9125, 9130-9133, 9135, 9136, 9141, 9142, 9161, 9170-9175, 9231, 9251, 9252, 9373, 9581	C000-C809	094
	8830	C000-C399, C440-C768, C809	094
	8963	C000-C639, C659-C699, C739-C768, C809	094
	9180, 9210, 9220, 9240	C490-C499	094
	9260	C000-C399, C470-C759	094
	9364	C000-C399, C470-C639, C659-C699, C739-C768, C809	094
	9365	C000-C399, C470-C639, C659-C768, C809	094
(e) Unspecified soft tissue sarcomas	8800-8805	C000-C399, C440-C768, C809	095
X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads			
(a) Intracranial and intraspinal germ cell tumors	9060-9065, 9070-9072, 9080-9085, 9100, 9101	C700-C729, C751-C753	101
(b) Malignant extracranial and extragonadal germ cell tumors	9060-9065, 9070-9072, 9080-9085, 9100-9105	C000-C559, C570-C619, C630-C699, C739-C750, C754-C768, C809	102
(c) Malignant gonadal germ cell tumors	9060-9065, 9070-9073, 9080-9085, 9090, 9091, 9100, 9101	C569, C620-C629	103
(d) Gonadal carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8143, 8190-8201,	C569, C620-C629	104

	8210, 8211, 8221-8241, 8244-8246, 8260-8263, 8290, 8310, 8313, 8320, 8323, 8380-8384, 8430, 8440, 8480-8490, 8504, 8510, 8550, 8560-8573, 9000, 9014, 9015		
	8441-8444, 8450, 8451, 8460-8473	C000-C809	104
(e) Other and unspecified malignant gonadal tumors	8590-8671	C000-C809	105
	8000-8005	C569, C620-C629	105
XI Other malignant epithelial neoplasms and malignant melanomas			
(a) Adrenocortical carcinomas	8370-8375	C000-C809	111
(b) Thyroid carcinomas	8010-8041, 8050-8075, 8082, 8120-8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8510, 8560-8573	C739	112
	8330-8337, 8340-8347, 8350	C000-C809	112
(c) Nasopharyngeal carcinomas	8010-8041, 8050-8075, 8082, 8083, 8120-8122, 8130-8141, 8190, 8200, 8201, 8211, 8230, 8231, 8244-8246, 8260-8263, 8290, 8310, 8320, 8323, 8430, 8440, 8480, 8481, 8500-8576	C110-C119	113
(d) Malignant melanomas	8720-8780, 8790	C000-C809	114
(e) Skin carcinomas	8010-8041, 8050-8075, 8078, 8082, 8090-8110, 8140, 8143, 8147, 8190, 8200, 8240, 8246, 8247, 8260, 8310, 8320, 8323, 8390-8420, 8430, 8480, 8542, 8560, 8570-8573, 8940, 8941	C440-C449	115
(f) Other and unspecified carcinomas	8010-8084, 8120-8157, 8190-8264, 8290, 8310, 8313-8315, 8320-8325, 8360, 8380-8384, 8430-8440, 8452-8454, 8480-8586, 8588-8589, 8940, 8941, 8983, 9000, 9010-9016, 9020, 9030	C000-C109, C129-C218, C239-C399, C480-C488, C500-C559, C570-C619, C630-C639, C659-C729, C750-C768, C809	116
XII Other and unspecified malignant neoplasms			
(a) Other specified malignant tumors	8930-8936, 8950, 8951, 8971-8981, 9050-9055, 9110	C000-C809	121
	9363	C000-C399, C470-C759	121
(b) Other unspecified malignant tumors	8000-8005	C000-C218, C239-C399, C420-C559, C570-C619, C630-C639, C659-C699, C739-C750, C754-C809	122
Not Classified by ICC or in situ			999

References

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Limited-Use, Nov 2008 Sub (1992-2006) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
 2. United States Cancer Statistics: 1999 - 2004 Incidence, WONDER On-line Database. United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; August 2008. Accessed at <http://wonder.cdc.gov/cancer-v2004.html> on June 4, 2009.
 3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. *Cancer*, 2005;103:1457-67.
 4. Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.5.1.
 5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2006) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released May 2009. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
-